NOV 04, 2019 11:44 AM PST

Gene Variant Could Be a Therapeutic Target For Alzheimer Disease

WRITTEN BY: Nouran Amin

A variation in genetics for an individual at high-risk for Alzheimer development has defied the odds for being dementia-free way beyond anticipated. The individual was a woman who carried a gene mutation prone to the development of early-onset Alzheimer but has not developed the symptoms until 30 years after the expected age of onset. Such observation led researchers on a study funded by the National Institute on Aging (NIA) that highly suggests how a gene variant could be the key to new target therapeutic.

Learn more about Alzheimer disease:

"Sometimes close analysis of a single case can lead to discovery that could have broad implications for the field," said NIA Director Richard J. Hodes, M.D. "We are encouraged that as part of our wide array of studies, this research in the unique genetic makeup of an exceptional individual can reveal helpful information."

In the study, researchers believe that the the woman who carried the gene mutation may have been protected from early Alzheimer symptoms because she also carried two copies of the APOE3 Christchurch (APOE3ch) gene variant. The variant was named after Christchurch, New Zealand were it was first identified.

Early-onset Alzheimer disease is heavily influenced by genetic factors and affects less than 10% of all people who have Alzheimer. The symptoms on average appear between 30 to 60 years of age. Experiments demonstrated in the study sought to address how the APOE3ch variant may reduce the brains ability from forming plaques—a hallmark of the disease.

Findings were published in the paper, “Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report” and shows how APOE3ch variant holds the potential to be a new way of treating or preventing Alzheimer disease.

Source: National Institute on Aging

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 16, 2020
Drug Discovery & Development
JAN 16, 2020
Fatty Acid Supplement Repairs Brain After Stroke in Mice
Researchers have found that supplements containing short chain fatty acids (SCFAs) may be able to help the brain recover from having a stroke. This comes a...
MAR 05, 2020
Drug Discovery & Development
MAR 05, 2020
Human Stem Cells Cure Type 1 Diabetes in Mice
In the US alone, around 187,000 children and adolescents have Type 1 diabetes, alongside 1.4 million people aged 20 and over. Managing their condition with...
MAR 08, 2020
Drug Discovery & Development
MAR 08, 2020
DNA Origami Helps With Cancer Therapeutics
A study published in the Proceedings of the National Academy of Sciences, describes how researchers designed molecules known as "peptoid-coated DNA or...
MAR 20, 2020
Drug Discovery & Development
MAR 20, 2020
WHO Says Ibuprofen May Still Work Against COVID-19
Since the announcement of a French Health Minister in recent days linking usage of ibuprofen and other non-steroidal anti-inflammatory medicines (NSAIDs) w...
MAR 28, 2020
Drug Discovery & Development
MAR 28, 2020
The Antibody Test to See if You've Already Had the Coronavirus
Knowing whether you’ve had the virus or not may not just reduce your need to panic- but also better help epidemiologists map out the spread of the vi...
MAR 31, 2020
Cancer
MAR 31, 2020
Ovarian cancer metastasis and CPT1A
Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado Cancer Center hits on new insight as...
Loading Comments...